| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Medallion | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $136.62M | Series C-1 | 9/2/2026 | $12M | $515.55M | $0.70 | Undisclosed Investors | ||||
 | RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $795.51M | Series D | 9/13/2022 | $159.75M | $599.64M | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | ||||
 | RefleXion Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $505.72M | Series F | 11/15/2023 | $106.71M | $874.99M | $1.50 | The Rise Fund, Pictet, Square Point Capital, Ally Bridge Group, Pfizer, Johnson & Johnson, T. Rowe Price, Venrock, Catalio Capital Management, Hillenbrand Capital Partners | ||||
 | Alma | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $441.06M | Series D | 8/25/2022 | $130M | $788.56M | $17.52 | Thoma Bravo, Cigna Ventures, Insight Partners, Optum Ventures, Tusk Venture Partners, Primary Venture Partners, Sound Ventures | ||||
 | American Gene Technologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $72.88M | Series F-1 | 12/3/2021 | $18M | $712.6M | $12.00 | Ride Wave Ventures, Alumni Ventures | ||||
 | Bambusa Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $142.98M | Series A-2 | 11/17/2025 | $40M | $539.54M | $18.73 | Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners, Salvia, Janus Henderson Investors, Invus, ADAR1 Capital Management, Dawn Biopharma | ||||
 | GATC Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $4.04M | Series Seed | 7/11/2023 | $4.04M | $500M | $5.60 | Undisclosed Investors | ||||
 | NexHealth | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $177.63M | Series C-2 | 4/21/2022 | $124.13M | $1B | $14.18 | Buckley Ventures, Lachy Groom, Jack Altman, Scott Belsky, Shreyas Doshi, Eric Glyman, Shahed Khan, Packy McCormick, Rahul Vohra | ||||
 | nference | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $293.57M | Series C | 12/15/2020 | $62.74M | $858.65M | $7.17 | Matrix Capital Management, Matrix Partners, Mayo Clinic Ventures, NTT Venture Capital | ||||
 | Tessera Therapeutics | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $587.85M | Series D | 12/1/2025 | $200M | $668.33M | $5.18 | Bill & Melinda Gates Foundation, Regeneron | ||||
 | Acelyrin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $558M | Series C | 9/9/2022 | $300M | $809.52M | $6.22 | Access Biotechnology, Matrix Capital Management, Westlake Village BioPartners, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital, Tybourne Capital Management, venBio Partners | ||||
 | Axtria | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $159.97M | Series E | 5/13/2021 | $100.1M | $920.88M | $9.53 | Bain Capital Tech Opportunities | ||||
 | Brightline | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $205.95M | Series C | 7/12/2022 | $115.2M | $705.25M | $8.73 | KKR, Northwell Health, GV, Optum Ventures, Oak HC/FT, Threshold Ventures, Blue Cross Blue Shield of Massachusetts | ||||
 | CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $510.76M | Series F | 8/2/2023 | $105.02M | $615.24M | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | ||||
 | Endeavor BioMedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $295.58M | Series C | 4/24/2024 | $132.58M | $676.04M | $6.52 | AyurMaya, Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, Woodline Partners, Abrdn Inc, Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, T. Rowe Price Associates | ||||
 | Found Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $132.31M | Series BB | 12/16/2021 | $100M | $601.15M | $1.83 | WestCap, IVP, The Chernin Group, G9 Ventures, Able Partners, GV, Atomic, Define Ventures, Fidji Simo, Julia Cheek | ||||
 | Medely | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $134.93M | Series C | 3/15/2022 | $90M | $735.36M | $32.61 | General Catalyst, Mayhaw Capital | ||||
 | Neurelis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $247.94M | Series D | 3/9/2021 | $114.76M | $544.18M | $3.15 | Cormorant Asset Management, Decheng Capital, LYZZ Capital, HBM Healthcare Investments, Philos & Partners SA | ||||
 | Notable | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $126.5M | Series B | 11/3/2021 | $100M | $600.67M | $3.49 | ICONIQ Growth, Greylock Partners, F-Prime Capital, Oak HC/FT | ||||
 | R-Zero | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $173.45M | Series C | 2/16/2023 | $105M | $526.86M | $14.13 | BMO Financial Group, Qualcomm Ventures, Upfront Ventures, DBL Partners, World Innovation Lab, Mayo Clinic, Bedrock Capital, SOSV, John Doerr | ||||
 | RapidAI | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $93.84M | Series C | 7/27/2023 | $75M | $667.51M | $55.44 | Vista Equity Partners | ||||
 | ReCode Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $397.77M | Series B | 9/23/2025 | $290M | $588.16M | $9.23 | Matrix Capital Management, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Bayer, Amgen, CF Foundation | ||||
 | Seaport Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $330.1M | Series B | 10/21/2024 | $226M | $725.46M | $14.92 | General Atlantic, T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs, CPP Investments, ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health | ||||
 | Sionna Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $331.32M | Series C | 3/6/2024 | $181.86M | $523.7M | $9.76 | Enavate Sciences, Viking Global Investors, Perceptive Advisors, RA Capital, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Qatar Investment Authority, OrbiMed | ||||